Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis.
F MettkeB SchlevogtK DeterdingA WrankeA SmithK PortM P MannsA VogelM CornbergHeiner WedemeyerPublished in: Alimentary pharmacology & therapeutics (2017)
IFN-free direct-acting antiviral therapy of chronic hepatitis C does not alter the short-term risk for HCC in patients with liver cirrhosis. A reduced HCC incidence may become evident after more than 1.5 years of follow-up.